Is lipase worth drawing at baseline before starting cagrilintide?

Setup, so nobody has to ask: lipase · cagrilintide.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

What should I decide now, and what should I defer?

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Keep the full report, not the number. You will need the units and the interval later.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

edited 19 Jul 2026 by carys_meredith — added the method parameters

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.